Back to Top Skip to main content Skip to sub-navigation

Early Detection Support for Troops During COVID-19

Woman in lab wearing mask and testing samples Lt. Cmdr. Danett Bishop, from Hawthorn Woods, Illinois, tests respiratory samples in the biological safety lab of amphibious assault ship USS America (LHA 6). (U.S. Navy photo by Mass Communication Specialist Seaman Jonathan Berlier)

Recommended Content:

Armed Forces Health Surveillance Division | Coronavirus

The quick spread of Coronavirus Disease 2019 has caused many health organizations including the Defense Health Agency’s Armed Forces Health Surveillance Division to innovate, using resources readily available in their arsenal.  

One example of this innovation lies within AFHSD’s Global Emerging Infections Surveillance (GEIS) program. The team funded the production of Research Use Only testing kits and sent them to GEIS laboratory partners located across the globe; targeting countries with high totals of positive COVID-19 cases. Navy mobile laboratories embedded on military ships, such as the USS Theodore Roosevelt received these kits. Military commanders then used the kits as respiratory surveillance tools on their sailors and Marines.

The Department of Defense funds the GEIS’s network of 16 medical research laboratories. This funding allowed the teams to quickly reach out to their partners and use their capabilities, such as the quick production of research assays, to support our forces. Assays are an investigative procedure in laboratory medicine that assess or measure the presence, amount, or activity of a military-relevant pathogen—in this case, the current coronavirus. This assay is similar to those created by the U.S. Centers for Disease Control and Prevention.

Two soldiers looking at computers
Hospital Corpsman 1st Class Ernesto Santa Ana, right, and Hospital Corpsman 2nd Class Maria F. Potts-Szoke work in Naval Medical Research Center's mobile laboratory aboard USS Theodore Roosevelt (CVN 71). (U.S. Navy/MCSN Kaylianna Genier)

“By rapidly distributing the RUO assays to our global partners and to three Navy mobile laboratories on shipboard settings, we were able to provide a much needed testing capability for this emerging pathogen in an operational environment,” explained U.S. Public Health Service Cmdr. (Dr.) Mark Scheckelhoff, who leads the respiratory infections focus area for GEIS. This assay supports surveillance studies only and not the clinical management of cases.

“The ability to procure and distribute the CDC RUO assay outside of a clinical laboratory setting provided a rapid and reliable source of COVID-19 testing and detection materials that were distributed to all of our network laboratories and allowed rapid implementation of testing activities,” said Scheckelhoff.

“As the COVID-19 cases began to increase around the world, military commanders in an operational environment had these RUO resources to conduct respiratory surveillance for COVID-19 exposure,” said Sean Friendly, chief of administration & operations at the AFHSD.

One recent example involved the Marine Corps Recruit Depot at Parris Island in South Carolina.  

"Our partner, the Naval Health Research Center laboratory was able to use their surveillance capabilities to provide the assistance to detect the first cases,” said Friendly.  He recounts a report from Dr. Chris Myers at NHRC in San Diego, California; the lab collected samples from the recruit population of Parris Island. GEIS-funded respiratory surveillance projects at NHRC provided the capability and personnel to test the recruits and quickly identify COVID-19.   

GEIS has worked with the NHRC for several years and supported ongoing surveillance of respiratory diseases among recruits and trainees. This network of health partners continues to grow and evolve as GEIS coordinates with NHRC as well as other network partners. The network’s ability to integrate the priorities identified by the Combatant Commands into its mission creates an agile organization ready to respond to needs as they occur.

Since 1997, GEIS has funded key laboratory/epidemiological work across the DoD. It has also coordinated crucial infectious disease surveillance projects that could impact military operations. GEIS uses key DoD medical research laboratories—such as the U.S. Army Medical Research Institute for Infectious Diseases, the Navy Medical Research Center, and the Walter Reed Army Institute of Research’s global lab enterprise in Maryland; and the Air Force School of Aerospace Medicine in Dayton, Ohio — to establish an integrated network that studies the impact of infectious diseases and respond to outbreaks and epidemics.

“In lay terms, GEIS’s projects and activities have allowed DoD to maintain world-wide critical surveillance capabilities that continue to provide crucial support during events of public health concern like the COVID-19 pandemic,” stated Navy Capt. Guillermo Pimentel, GEIS chief.

You also may be interested in...

DHA-PI 6205.01: Medical Logistics Guidance for the DoD Coronavirus Disease 2019 (COVID-19) Vaccination Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (n), establishes the Defense Health Agency's (DHA's) procedures for ordering, receiving, and managing COVID-19 Vaccines inventory and ancillary kits.

DHA-IPM 20-004: Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation

Policy

This Defense Health Agency (DHA) Interim Procedures Memorandum (IPM), based on the authority of References (a) through (d), and in accordance with the guidance cited in References (e) through (aa), establishes the DHA’s procedures to implement instructions, assign responsibilities, and prescribe procedures for the COVID-19 Vaccination Program. This DHA-IPM applies to DHA, DHA Components (activities under the authority direction, and control of the DHA), Military Departments (MILDEP), and the United States Coast Guard (CG). This DHA-IPM cancels and replaces DHA-IPM 20-004, “Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation,” December 13, 2020.

TAB A MEO COVID19 Medical Coding Policy

Policy

Memorandum for DHA Staff - Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

  • Identification #: N/A
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus

DHA COVID19 Medical Coding PolicyV5 1v

Policy

Establishes the DHA procedures to standardize the coding for Coronavirus 2019 (COVID-19) within military medical treatment facilities (MTFs). This memorandum replaces DHA-Policy Memorandum 20-003 of July 1, 2020. Attachment 1 was updated to include the 2021 procedure and diagnosis codes for COVID-19, including the new vaccination and treatment codes.

  • Identification #: 20-003
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus

Supplemental Guidance for Providing DoD Coronavirus Disease 2019 Vaccines to DoD Contractor Employees and Select Foreign Nationals

Policy

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components as appropriate.

HA Guidance for Coronavirus Disease 2019 (COVID-19) Laboratory Pre-Testing Questionnaire

Policy

This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DoD beneficiaries treated at military medical treatment facilities.

Executive Order on Ensuring Access to United States Government COVID-19 Vaccines

Policy

This EO outlines who should receive priority access to COVID-19 vaccines developed in the United States or procured by the United States Government (“United States Government COVID-19 Vaccines”).

Coronavirus Disease 2019 Vaccine Guidance

Policy

This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components.

DHA-AI 3020-01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), based on the authority of References (a) through (b) and in accordance with the guidance of References (c) through (z3), establishes the Defense Health Agency's (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic. This DHA-AI also provides a preventive plan to monitor and assess for the appearance of new cases and implement those processes that will prevent them from impacting the workforce. The processes describe herein are intended to offer an actionable plan for the workforce to re-enter DHA Administrative Offices. See Appendix 1 for a summary of the DHA Administrative Office Reopening Plan. The plan uses the Force Health Protection Guidance and Health Protection Conditions (HPCON), in accordance with Reference (d), to ensure protection for the workforce, including the most vulnerable-to-serious complications from the virus while enabling DHA Administrative Offices to continue its mission. See Appendix 2 for the conceptual HPCON framework.

  • Identification #: 3020-01
  • Date: 11/3/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus

DHA AI 3020.01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 (COVID-19) Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), establishes the Defense Health Agency’s (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic and in preparation for regression or resurgence in COVID-19 cases that could impact the workforce.

  • Identification #: DHA AI 3020.01
  • Date: 6/12/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus

Armed Forces Reportable Medical Events Guidelines and Case Definitions Memo

Policy

The Armed Forces Reportable Medical Events Guidelines and Case Definitions (RME Guidelines) standardize reporting and tracking of disease and other conditions of public health and military importance. Timely reporting permits earlier recognition of public health events and interventions to protect the health of the force.

Showing results 1 - 11 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.